Sanofi CFO Jean-Baptiste de Chatillon (L) and CEO Paul Hudson (Romuald Meigneux/Sipa via AP Images)
February 3, 2023 03:11 PM EST
Pharma

Sanofi sees downtick in flu sales as it preps for launch of RSV an­ti­body

Tyler Patchen

News Reporter

Sanofi ex­pects its RSV an­ti­body joint­ly de­vel­oped with As­traZeneca will be avail­able next sea­son, ex­ec­u­tive VP of vac­cines Thomas Tri­om­phe an­nounced on the com­pa­ny’s quar­ter­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times